Axonics Modulation Technologies (NSDQ:AXNX) said today that the underwriters behinds its $120 million initial public offering exercised their over-allotment option, adding another $18 million to its coffers. Irvine, Calif.-based Axonics, which makes the r-SNM device sacral neuromodulation system for treating overactive bladder, fecal incontinence and urinary retention, said the underwriters picked up 1.2 million shares at $15 each, taking […]
Abbott wins CE Mark, FDA nod for DRG Invisible Trial neuromod system
Abbott (NYSE:ABT) said today that it won FDA clearance and CE Mark approval in the European Union for its DRG Invisible Trial System intended to allow patients with complex chronic pain conditions to receive a trial treatment with the company’s dorsal root ganglion stimulation system. Abbott’s DRG therapy targets the dorsal root ganglion, a structure adjacent to […]
Nevro posts Q3 earnings miss, sales beat
Nevro Corp. (NYSE:NVRO) yesterday posted third-quarter results that missed the consensus earnings forecast but beat on revenues. The Redwood City, Calif.-based neuromodulation firm reported losses of -$11.2 million, or -37¢ per share, on sales of $95.6 million for the three months ended Sept. 30, widening its losses by 84.3% on 16.3% sales growth compared with Q3 […]
NIH invests over $220M in BRAIN initiative
The National Institutes of Health announced today that it is funding more than 200 new awards, totaling over $220 million in investments, through the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative. Some of the new awards include the creation of a wireless optical tomography cap for scanning human brain activity; a noninvasive brain-computer interface […]
Axonics closes $120m IPO
Axonics Modulation Technologies (NSDQ:AXNX) today closed its $120 million initial public offering, saying it could reap still more from the flotation if an underwriters option is exercised. Irvine, Calif.-based Axonics, which makes the r-SNM device sacral neuromodulation system for treating overactive bladder, fecal incontinence and urinary retention, had set the range for the flotation at $93.3 million to $106.7 million, but […]
Axonics prices upsized $120m offering
Axonics Modulation Technologies yesterday priced an upsized initial public offering that could fetch a maximum of $138 million. Irvine, Calif.-based Axonics, which makes the r-SNM device sacral neuromodulation system for treating overactive bladder, fecal incontinence and urinary retention, last week set the range for the flotation at $93.3 million to $106.7 million, saying it would issue nearly 6.7 million shares […]
Axonics sets range for $100m IPO
Axonics Modulation Technologies yesterday set the range on an initial public offering that would fetch $100 million at the midpoint. The Irvine, Calif.-based company makes the r-SNM device sacral neuromodulation system for treating overactive bladder, fecal incontinence and urinary retention. Axonics touts it as the first such rechargeable device; it’s designed to deliver mild electrical stimulation using a four-electrode […]
Abbott alleges ex-marketing exec lifted its neuromod marketing playbook
Abbott (NYSE:ABT) this week accused a former marketing executive of purloining the marketing playbook for its neuromodulation business on his way out the door to a marketing job at competitor Nevro Corp. (NYSE:NVRO). In a lawsuit filed in the U.S. District Court for Northern Illinois, Abbott alleged that former neuromodulation global marketing product manager Blayne […]
Axonics Modulation files for $86m IPO
Axonics Modulation Technologies last week registered for an initial public offering worth more than $86 million for its neuromodulation system for treating urinary and bowel conditions. The Irvine, Calif.-based company touts its r-SNM device as the first rechargeable sacral neuromodulation system for treating overactive bladder, fecal incontinence and urinary retention. It’s designed to deliver mild electrical stimulation using […]
MedAutonomic implants device to treat metabolic syndrome
MedAutonomic said today it has successfully implanted a brain neuromodulation device, the Phoenix, into the stomach wall of a human through an innovative digestive endoscopic procedure. Powered without a battery, the Phoenix sends signals to the limbic system to reset an imbalance in the autonomic nervous system to treat metabolic syndrome and functional diseases […]
LivaNova launches pivotal study for Vitaria heart failure device
LivaNova (NSDQ:LIVN) said today that it launched a pivotal study of its Vitaria neuromodulation implant for treating heart failure. The 800-patient Anthem-HFrEF study’s first subject was implanted with the Vitaria vagus nerve stimulation device at St. Luke’s Hospital in Cedar Rapids, Iowa, the London-based company said. Patients enrolled in the trial are slated to be randomized on […]
- 1
- 2
- 3
- …
- 49
- Next Page »
MassDevice Network
@MassDevice
LinkedIn